NCT06594679View on ClinicalTrials.gov

A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

73

Participants

Timeline

Start Date

September 26, 2024

Primary Completion Date

March 20, 2027

Study Completion Date

September 18, 2027

Conditions

Ovarian Cancer

Interventions

DRUG

Niraparib Tosylate Monohydrate

Combination of niraparib and abemaciclib

Trial Locations (1)

20133

RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER

NCT06594679 - A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL) | Biotech Hunter | Biotech Hunter